US vaccine giant Moderna announced the efficacy of its COVID-19, which the company said is 90% against all forms of the disease and 95% in case of severe disease.

The new results are from the ongoing Phase 3 clinical trial involving more 30,000 people across the United States, and the headline efficacy figure is a slight decrease from an earlier figure of 94.1% published in the New England Journal of Medicine in December.

Also read: China mulls mixing vaccines to improve efficacy of jabs

The new number is based on 900 adjudicated cases of COVID-19 from the study as of April 9, while the previous was based on 185 cases.

A company did not say anything on why the vaccine efficacy has fallen, but speculations are that the number has fallen due to the emergence of new variants which are not as susceptible to antibodies evoked to the vaccine.

Moderna is working on two variant-specific boosters, and said mice studies showed they elicited an increased immune response. The results of these studies have been posted online in a scientific paper that is now awaiting peer review.

“The new preclinical data on our variant-specific vaccine candidates give us confidence that we can proactively address emerging variants,” said CEO Stephane Bancel.

Also read: J&J vaccine: Risks and symptoms related to COVID-19 shot

The company said that as of April 12, it has delivered 132 million doses of its vaccine globally, including approximately 117 million doses to the United States.

It remains on course to deliver 100 million more doses by the end of May followed by 100 million more by the end of June.

The company’s clinical trial for adolescents aged 12 to 17 is now fully enrolled with 3,000 US participants, and its pediatric trial for children aged six months to 11 years is continuing to enroll its 6,750 participants in the United States and China.